IRIS Accounts Production v24.3.0.553 10173930 director 1.6.23 31.5.24 31.5.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh101739302023-05-31101739302024-05-31101739302023-06-012024-05-31101739302022-05-31101739302022-06-012023-05-31101739302023-05-3110173930ns15:EnglandWales2023-06-012024-05-3110173930ns14:PoundSterling2023-06-012024-05-3110173930ns10:Director12023-06-012024-05-3110173930ns10:PrivateLimitedCompanyLtd2023-06-012024-05-3110173930ns10:SmallEntities2023-06-012024-05-3110173930ns10:AuditExemptWithAccountantsReport2023-06-012024-05-3110173930ns10:SmallCompaniesRegimeForDirectorsReport2023-06-012024-05-3110173930ns10:SmallCompaniesRegimeForAccounts2023-06-012024-05-3110173930ns10:FullAccounts2023-06-012024-05-3110173930ns10:OrdinaryShareClass12023-06-012024-05-3110173930ns10:RegisteredOffice2023-06-012024-05-3110173930ns5:CurrentFinancialInstruments2024-05-3110173930ns5:CurrentFinancialInstruments2023-05-3110173930ns5:ShareCapital2024-05-3110173930ns5:ShareCapital2023-05-3110173930ns5:RetainedEarningsAccumulatedLosses2024-05-3110173930ns5:RetainedEarningsAccumulatedLosses2023-05-3110173930ns5:PlantMachinery2023-06-012024-05-3110173930ns5:ComputerEquipment2023-06-012024-05-3110173930ns5:PlantMachinery2023-05-3110173930ns5:ComputerEquipment2023-05-3110173930ns5:PlantMachinery2024-05-3110173930ns5:ComputerEquipment2024-05-3110173930ns5:PlantMachinery2023-05-3110173930ns5:ComputerEquipment2023-05-3110173930ns10:OrdinaryShareClass12024-05-3110173930ns5:RetainedEarningsAccumulatedLosses2023-05-3110173930ns5:RetainedEarningsAccumulatedLosses2023-06-012024-05-31
REGISTERED NUMBER: 10173930 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 May 2024

for

Pharmadagio Limited

Pharmadagio Limited (Registered number: 10173930)






Contents of the Financial Statements
for the Year Ended 31 May 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Report of the Accountants 6

Pharmadagio Limited

Company Information
for the Year Ended 31 May 2024







DIRECTOR: M Perry





REGISTERED OFFICE: 26 Bell Street
Sawbridgeworth
Hertfordshire
CM21 9AN





REGISTERED NUMBER: 10173930 (England and Wales)





ACCOUNTANTS: Lawrence & Company
Chartered Certified Accountants
26 Bell Street
Sawbridgeworth
Hertfordshire
CM21 9AN

Pharmadagio Limited (Registered number: 10173930)

Balance Sheet
31 May 2024

31.5.24 31.5.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 2,622 3,677

CURRENT ASSETS
Debtors 5 82,180 61,343
Cash at bank 86,542 117,739
168,722 179,082
CREDITORS
Amounts falling due within one year 6 35,802 32,466
NET CURRENT ASSETS 132,920 146,616
TOTAL ASSETS LESS CURRENT
LIABILITIES

135,542

150,293

CAPITAL AND RESERVES
Called up share capital 7 100 100
Retained earnings 8 135,442 150,193
SHAREHOLDERS' FUNDS 135,542 150,293

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 21 October 2024 and were signed by:





M Perry - Director


Pharmadagio Limited (Registered number: 10173930)

Notes to the Financial Statements
for the Year Ended 31 May 2024

1. STATUTORY INFORMATION

Pharmadagio Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 25% on reducing balance
Computer equipment - 25% on cost

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

Pharmadagio Limited (Registered number: 10173930)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

4. TANGIBLE FIXED ASSETS
Plant and Computer
machinery equipment Totals
£    £    £   
COST
At 1 June 2023
and 31 May 2024 11,435 3,817 15,252
DEPRECIATION
At 1 June 2023 8,299 3,276 11,575
Charge for year 784 271 1,055
At 31 May 2024 9,083 3,547 12,630
NET BOOK VALUE
At 31 May 2024 2,352 270 2,622
At 31 May 2023 3,136 541 3,677

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Trade debtors 82,180 61,343

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.24 31.5.23
£    £   
Trade creditors 27,776 10,404
Taxation 5,114 13,530
Social security and other taxes 1,712 3,332
Directors' current accounts - 4,000
Accrued expenses 1,200 1,200
35,802 32,466

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.5.24 31.5.23
value: £    £   
100 Ordinary £1 100 100

8. RESERVES
Retained
earnings
£   

At 1 June 2023 150,193
Profit for the year 20,749
Dividends (35,500 )
At 31 May 2024 135,442

Pharmadagio Limited (Registered number: 10173930)

Notes to the Financial Statements - continued
for the Year Ended 31 May 2024

9. RELATED PARTY DISCLOSURES

During the year, total dividends of £35,500 (2023 - £35,000) were paid to the director .

The director controls the company by virtue of a direct controlling interest of 100% of the issued ordinary share capital. Transactions on the directors loan account during the year were as follows:-


Balance Repaid by Balance
B/fwd the company C/fwd

£4,000 £4,000 £Nil

Pharmadagio Limited

Report of the Accountants to the Director of
Pharmadagio Limited

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 May 2024 set out on pages three to seven and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Lawrence & Company
Chartered Certified Accountants
26 Bell Street
Sawbridgeworth
Hertfordshire
CM21 9AN


21 October 2024